Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Mechanism of metastasis is discovered in pancreatic cancer

The Lustgarten Foundation for Pancreatic Cancer Research
Posted on: 29 Jul 17

WOODBURY, N.Y., July 27, 2017 /PRNewswire-USNewswire/ -- Lustgarten Foundation funded research discovered a mechanism of metastasis in pancreatic cancer, and perhaps, other cancer types as well. The Foundation's dedicated lab at Cold Spring Harbor Laboratory (CSHL) used organoid technology to find that pancreatic cancer cells reprogram gene enhancers to achieve the ability to spread.

The research, appearing online today in Cell, provides strong evidence supporting this explanation of metastasis, which is the cause of most cancer deaths. Experiments conducted by postdoctoral investigators of the Vakoc and Tuveson labs at CSHL, focused on cells of the pancreas since most pancreatic cancer cases culminate in metastasis.

"We show that to metastasize, the cell has to change, in effect, its whole telecommunications network – its enhancers are being reprogrammed," Vakoc says. "It seems quite plausible from our results that reprogramming of enhancers enables cancer cells, generally, to achieve metastatic competence."

The Vakoc team used pancreatic organoid technology developed in the lab of Professor David Tuveson, Director of CSHL's Cancer Center and Director of Research for the Lustgarten Foundation.  Organoids enabled the team to compare normal pancreatic ductal cells in six mice with cells from the same animals in three distinct stages: premalignant, malignant, and metastatic. The team tracked down an epigenetic agent, called FOXA1, whose increased activity causes the reprogramming.

The discovery could have major implications for understanding and treating metastatic cancer. By understanding the biochemical changes that trigger metastasis, eventually researchers will be able to screen potential drugs to suppress these biochemical changes and stop the cancer from metastasizing.

The paper can be viewed at: http://www.cell.com/cell/newarticles

About the Lustgarten Foundation
The Lustgarten Foundation is America's largest private foundation dedicated to funding pancreatic cancer research. Based in Woodbury, NY, the Foundation supports research to find a cure for pancreatic cancer. Since its inception, the Lustgarten Foundation has directed $132 million to research. For more information, please visit www.lustgarten.org.

About Cold Spring Harbor Laboratory
Founded in 1890, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. For more information, visit www.cshl.edu

For more information:
www.lustgarten.org

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 29/07/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.